Early antithrombotic therapy and COVID-19: a better clinical course? New evidences from real-life cases

Casale, M.; Imbalzano, E.; Morabito, C.; de Fazio, M. G.; Crea, P.; Mezzetti, M.; Busacca, P.; Correale, M.; Signorelli, S. S.; Dattilo, G.

Casale, M.; Imbalzano, E.; Morabito, C.; de Fazio, M. G.; Crea, P.; Mezzetti, M.; Busacca, P.; Correale, M.; Signorelli, S. S.; Dattilo, G..

Cor et Vasa ; 62(1):37-40, 2020.

Article in English | Scopus | ID: covidwho-823377

ABSTRACT

ABSTRACT

The recent COVID-19 carries potential risk factors for VTE and worse clinical course in some patients has an association with thrombosis. While low molecular weight heparins are under investigation for appropriate dosage, other elements could be useful. We share our experience about two patients with unexpected clinical course. © 2020 Czech Society of Cardiology Z.S. All rights reserved.

Fulltext

XML

Search on Google

Full text: Available Collection: Databases of international organizations Database: Scopus Type of study: Prognostic study Language: English Journal: Cor et Vasa Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google